
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics Inc. has demonstrated a positive trajectory in its clinical development, notably through statistically significant increases in Treg numbers and suppressive function within just two weeks, sustaining these enhancements throughout a 22-week treatment period. The successful proof of concept study for COYA 302 in frontotemporal dementia, which showed robust regulatory T cell engagement and cognitive stability, strengthens the company’s positioning as a potential leader in addressing neurodegenerative diseases with high unmet needs. Additionally, the favorable safety profile observed in clinical trials, combined with recent FDA clearance, underscores the company's advancing Treg-focused therapeutic platform.
Bears say
Coya Therapeutics Inc faces significant risks that could adversely affect its financial performance and valuation, primarily related to potential obsolescence of its therapies due to advancements in treatment methods for neurodegenerative, autoimmune, and metabolic diseases. The company also struggles with the adequacy of its intellectual property protection, which poses further risks of costly legal challenges that could divert resources and financial focus. Additionally, Coya's ongoing cash burn necessitates the likelihood of raising additional capital for operations, amplifying concerns about its long-term financial stability and viability in the competitive biotechnology landscape.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares